Under the Oncology Care Model (OCM), there's a wide range of practice sizes, creating challenges for evaluation, said Basit Chaudhry, MD, PhD, founder of Tuple Health.
Under the Oncology Care Model (OCM), there's a wide range of practice sizes, creating challenges for evaluation, said Basit Chaudhry, MD, PhD, founder of Tuple Health.
Transcript
Why is it important for OCM evaluation to take into consideration differences among participating practices?
One of the things that’s very different about OCM, in part because of the selection criteria for entering the model, it was really oriented around practices in the community or outpatient setting. What this has done is the participants inside of OCM, there’s often a scale order of difference in how large they are. So, this is a kind of interesting thing. In other CMMI [Center for Medicare and Medicaid Innovation] models, you don’t have this kind of massive difference in scale. There’s, I believe, a practice that’s a 1-physician practice in OCM and there’s a 300-physician practice in OCM. This creates real challenges on the evaluation, because if you’re trying to essentially match practices as comparisons, it becomes very difficult because of the very skewed distribution.
The evaluation of this model is also particularly important because due to the complexity of cancer care on the model itself, there have been a number of methodologic changes that have been made along the way. So, in a way, it’s a moving target over what OCM performance is, so the evaluators I think, have a very important job to think about how do we really assess what the impact of this payment model has been. That’s especially important in this model, and it’s key to all CMMI models, but it’s especially important in OCM. There’s a lot of decisions that will need to be made on how the evaluation will be done, so it will be interesting to see how that works.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More